Consensus Augmedix, Inc.

Equities

AUGX

US05105P1075

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.9166 ^USD	+0.94%		-8.34%	-84.33%

Jun. 26	Augmedix, Inc. and Augmedix Operating Corporation Enter into That Certain Second Amendment to Loan and Security Agreement	CI
Jun. 20	Emergency Services Inc. Partners with Augmedix to Introduce Generative Ai Solution That Relieves Clinician Burnout in Emergency Departments	CI

Evolution of the average Target Price on Augmedix, Inc.

Price target over the last 5 years

History of analyst recommendation changes

8e41aea1.h1hqSlIWtOinadJtd0FykpO1LlmyZwIzKlEfSZFRA54.5C4CBj942ofDHKIsEwkAyOWNXm_AKUN0dSNbIOApNO21OQQaEVXsxco9iw~1f94c624934ad75c1a8cbaa87c5bba29

Analyst Recommendations on Augmedix, Inc.

Maxim Downgrades Augmedix to Hold From Buy	May. 14	MT
B. Riley Adjusts Price Target on Augmedix to $3 From $5.50, Keeps Buy Rating	May. 14	MT
Evercore ISI Downgrades Augmedix to In Line From Outperform, Price Target is $1.50	May. 14	MT
Augmedix Insider Sold Shares Worth $369,285, According to a Recent SEC Filing	Apr. 12	MT
Augmedix Insider Sold Shares Worth $454,454, According to a Recent SEC Filing	Apr. 05	MT
Augmedix Insider Sold Shares Worth $380,108, According to a Recent SEC Filing	Apr. 04	MT
Evercore ISI Adjusts Price Target on Augmedix to $4.50 From $6.50, Maintains In-Line Rating	Mar. 19	MT
Evercore ISI Initiates Augmedix With In Line Rating, Price Target is $6	Dec. 15	MT
B. Riley Lifts Augmedix's PT to $7.50 From $6.50, Raises 2023 Outlook, Notes Increased Confidence in Business Trajectory; Maintains Buy Rating	Nov. 07	MT
B. Riley Lifts Augmedix's PT to $6.50 From $5.50 on Raised 2023 Outlook, Increased Confidence in Business Trajectory; Keeps Buy Rating	23-08-08	MT
B. Riley Lifts Augmedix's Price Target to $5.50 From $5 After Q1 Topline Beat, 'Strong' Q2 Guide; Keeps Buy Rating	23-05-15	MT
Benchmark Adjusts Price Target on Augmedix to $6 From $5, Maintains Buy Rating	23-04-21	MT
Maxim Group Adjusts Price Target on Augmedix to $8 From $5, Maintains Buy Rating	23-04-21	MT
B. Riley Lifts Augmedix's Price Target to $5 From $4 on Heels of Announced HCA Healthcare Partnership, Strategic Investment; Keeps Buy Rating	23-04-21	MT
Maxim Adjusts Price Target on Augmedix to $5 From $4, Maintains Buy Rating	23-03-28	MT
B. Riley Resumes Augmedix at Buy With $4 Price Target	22-12-29	MT
B. Riley Lowers Augmedix's Price Target to $4.50 from $6.50 Based on Lower 2023 Enterprise Value/Sales Multiple, Keeps Buy Rating	22-08-01	MT
Lake Street Initiates Augmedix at Buy with $6 Price Target	22-03-07	MT
Maxim Starts Augmedix at Buy with $6 Price Target	22-01-21	MT
Maxim Starts Augmedix at Buy With $6 Price Target	22-01-21	MT
William Blair Initiates Coverage on Augmedix With Outperform Rating	21-11-01	MT
Benchmark Starts Augmedix at Buy With $6 Price Target	21-11-01	MT
B. Riley Resumes Augmedix at Buy with $6.50 PT, Says Recent Capital Raise/Uplisting to Nasdaq Supports Growth Strategy Execution	21-10-29	MT